TY - JOUR
T1 - The burden of atopic dermatitis in Portuguese patients
T2 - an observational study
AU - Coelho, Pedro Simões
AU - Apalhão, Miguel
AU - Victorino, Guilherme
AU - Cardoso, Cristina
AU - Camilo, Joana
AU - Silva, João Maia
N1 - Coelho, P. S., Apalhão, M., Victorino, G., Cardoso, C., Camilo, J., & Silva, J. M. (2024). The burden of atopic dermatitis in Portuguese patients: an observational study. Scientific Reports, 14, 1-8. Article 5181. https://doi.org/10.1038/s41598-024-55965-y --- The study was conducted with the support of NOVA IMS, SPDV and ADERMAP and was funded by Sanofi
PY - 2024/3/2
Y1 - 2024/3/2
N2 - Atopic dermatitis (AD) is a common inflammatory skin condition that significantly affects patients' lives and imposes both economic and non-economic burdens. The precise societal and individual consequences of AD remain incompletely understood. This study aimed to characterize AD in Portuguese patients and assess its personal, familial, and societal implications, including health status and quality of life. The research, conducted from June 2019 to January 2020, involved 204 confirmed AD patients in Portugal, who completed a 70-question questionnaire. Results show that, on average, patients experienced a two-year delay in diagnosis, with two-thirds having allergic comorbidities. Late-onset AD (after age 20) was found to be correlated with worsening symptoms post-diagnosis. Globally, patients reported substantial effects on health, quality of life, and mental well-being. Effects include significant levels of anxiety, frustration and sleep disorders. Severe AD correlated with more suffering and reduced perceived health, indicating a link between disease severity and quality of life. Remarkably, despite questionable effectiveness, 92% of severe AD patients were prescribed antihistamines, while only 19% received biological treatments. In Portugal, delayed AD diagnosis hinders timely treatment, and despite its profound impact and high comorbidity rates, AD patients tend to remain undertreated. Recognizing the personal and societal repercussions is crucial for enhancing care, contributing to improving QoL, social functioning and global well-being.
AB - Atopic dermatitis (AD) is a common inflammatory skin condition that significantly affects patients' lives and imposes both economic and non-economic burdens. The precise societal and individual consequences of AD remain incompletely understood. This study aimed to characterize AD in Portuguese patients and assess its personal, familial, and societal implications, including health status and quality of life. The research, conducted from June 2019 to January 2020, involved 204 confirmed AD patients in Portugal, who completed a 70-question questionnaire. Results show that, on average, patients experienced a two-year delay in diagnosis, with two-thirds having allergic comorbidities. Late-onset AD (after age 20) was found to be correlated with worsening symptoms post-diagnosis. Globally, patients reported substantial effects on health, quality of life, and mental well-being. Effects include significant levels of anxiety, frustration and sleep disorders. Severe AD correlated with more suffering and reduced perceived health, indicating a link between disease severity and quality of life. Remarkably, despite questionable effectiveness, 92% of severe AD patients were prescribed antihistamines, while only 19% received biological treatments. In Portugal, delayed AD diagnosis hinders timely treatment, and despite its profound impact and high comorbidity rates, AD patients tend to remain undertreated. Recognizing the personal and societal repercussions is crucial for enhancing care, contributing to improving QoL, social functioning and global well-being.
UR - https://www.webofscience.com/wos/woscc/full-record/WOS:001179809500037
UR - http://www.scopus.com/inward/record.url?scp=85186429587&partnerID=8YFLogxK
U2 - 10.1038/s41598-024-55965-y
DO - 10.1038/s41598-024-55965-y
M3 - Article
C2 - 38431751
SN - 2045-2322
VL - 14
SP - 1
EP - 8
JO - Scientific Reports
JF - Scientific Reports
M1 - 5181
ER -